<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321085</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0811</org_study_id>
    <nct_id>NCT02321085</nct_id>
  </id_info>
  <brief_title>The Comparison With Clinical Impacts on Functional Capacity and Symptom Improvement According to the Rhythm Control in Patients With Heart Failure and Recent Onset Atrial Fibrillation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized (rhythm control or rate control in heart failure patients with new&#xD;
      onset atrial fibrillation) Objective of study 1. To analyze long term outcome of patients&#xD;
      with heart failure with new onset atrial fibrillation according to the rhythm control 2. To&#xD;
      analyze remodeling of atrium and ventricle by the new onset AF in heart failure patients 3.&#xD;
      To analyze the change of LV function and functional capacity according to the rhythm in&#xD;
      patients with HF and new onset AF&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of left ventricular function according to the rhythm control in patient with heart failure and new onset atrial fibrillation</measure>
    <time_frame>1 year</time_frame>
    <description>ejection fraction change (echocardiography)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functional capacity according to the rhythm control in patient with heart failure and new onset atrial fibrillation</measure>
    <time_frame>1 year</time_frame>
    <description>peak VO2 (cardio pulmonary test ; CPX)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>remodeling of atrium by the new onset AF in heart failure patients The change of LV function and functional capacity according to the rhythm in patients with HF and new onset AF</measure>
    <time_frame>1 years late</time_frame>
    <description>Echo cardiography (LV ejection fraction, LV wall thickness, LV mass index, LA dimension, LA appendage velocity, E/E'), EKG, 24 hours Holter recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remodeling of ventricle by the new onset AF in heart failure patients The change of LV function and functional capacity according to the rhythm in patients with HF and new onset AF</measure>
    <time_frame>1 years late</time_frame>
    <description>Echo cardiography (LV ejection fraction, LV wall thickness, LV mass index, LA dimension, LA appendage velocity, E/E'), EKG, 24 hours Holter recording</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Heart Failure</condition>
  <condition>Recent Onset Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Sinus Rhythm Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation&#xD;
Cardioversion after 1 month&#xD;
Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)&#xD;
If AF recur, RFCA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulse Rate Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No AAD, just anticoagulation&#xD;
HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)&#xD;
Without the treatment about antiarrhythmia and rhythm control, diffraction of rate control, the subject will be drop out for study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sinus Rhythm control</intervention_name>
    <arm_group_label>Sinus Rhythm Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulse Rate control</intervention_name>
    <arm_group_label>Pulse Rate Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with Heart failure and Atrial fibrillation within 1year (20~80 years old)&#xD;
&#xD;
          2. LA diameter &lt; 5mm&#xD;
&#xD;
          3. LVEF 20~49%&#xD;
&#xD;
          4. patients possible to anticoagulation and anti arrhythmic drug&#xD;
&#xD;
          5. Expected survival &gt;1yr&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Impossible to anticoagulation or anti arrhythmic drug&#xD;
&#xD;
          2. valvular atrial fibrillation ( Mitral valve stenosis, Mitral valve plasty, valve&#xD;
             replacement)&#xD;
&#xD;
          3. LV ejection fraction &lt; 20%&#xD;
&#xD;
          4. Structural cardiac disease&#xD;
&#xD;
          5. Catheter ablation history for AF, maze surgery&#xD;
&#xD;
          6. patient with severe medical disease&#xD;
&#xD;
          7. Impossible to anticoagulation or anti arrhythmic drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui-Nam Pak, MD</last_name>
    <phone>+82-2-2228-8459</phone>
    <email>hnpak@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

